The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Preparing for Preventive Clinical Trials: The Predict-HD Study
Abstract
BACKGROUND: The optimal design and outcome measures for preventive clinical trials in neurodegenerative diseases are unknown. OBJECTIVE: To examine measures that may be associated with disease in the largest cohort ever recruited of prediagnosed individuals carrying the gene expansion for Huntington disease (HD). DESIGN: The Predict-HD study is a multicenter observational research study in progress at 17 sites in the United States, 4 in Canada, and 3 in Australia. SETTING: Genetics and HD outpatient clinics. PARTICIPANTS: Five hundred five at-risk individuals who had previously undergone elective DNA analyses for the CAG expansion in the HD gene (predictive testing) and did not currently have a clinical diagnosis of HD. MAIN OUTCOME MEASURES: Basal ganglia volumes on magnetic resonance images, estimated probability of diagnosis (based on CAG repeat length), performances on 21 standardized cognitive tasks, total scores on 3 scales of psychiatric distress, and motor diagnosis based on the Unified Huntington's Disease Rating Scale. RESULTS: Several variables showed progressive decline as the diagnostic ratings advanced toward manifest disease. Estimated probability of diagnosis was associated with Unified Huntington's Disease Rating Scale prediagnostic stages and varied from 15% in persons with no motor abnormalities to nearly 40% in those with abnormalities suggestive of probable disease. Striatal volumes, cognitive performances, and even psychiatric ratings declined significantly with motor manifestations of disease. CONCLUSIONS: The documentation of biological and refined clinical markers suggests several clinical end points for preventive clinical trials. Longitudinal study is critical to further validate possible markers for prediagnosed HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
The Sequence of the Human Genome
Venter, J. C., Smith, H. O., & Adams, M. D. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.237016 · Cited by 1,648
Unified Huntington's disease rating scale: reliability and consistency
Kremer, H. P. H. (1996) · Radboud Repository (Radboud University) · Cited by 1,059
National Trends in the Outpatient Treatment of Depression
Olfson, M. (2002) · JAMA · doi:10.1001/jama.287.2.203 · Cited by 847
Langbehn, D., Brinkman, R., Falush, D., Paulsen, J., Hayden, M., & on behalf of an International Huntington's Disease Collaborative Group (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00241.x · Cited by 817
Self-citationPrevalence of suicide ideation and suicide attempts in nine countries
WEISSMAN, M. M., BLAND, R. C., CANINO, G. J., GREENWALD, S., HWU, H.-G., JOYCE, P. R., KARAM, E. G., LEE, C.-K., LELLOUCH, J., LEPINE, J.-P., et al. (1999) · Psychological Medicine · doi:10.1017/s0033291798007867 · Cited by 582
Onset and rate of striatal atrophy in preclinical Huntington disease
Aylward, E. H., Sparks, B. F., Field, K. M., Yallapragada, V., Shpritz, B. D., Rosenblatt, A., Brandt, J., Gourley, L. M., Liang, K., Zhou, H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000132965.14653.d1 · Cited by 408
Basal ganglia volumes and white matter hyperintensities in patients with bipolar disorder
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.5.687 · Cited by 275
Warner, J. P., Barron, L. H., & Brock, D. J. H. (1993) · Molecular and Cellular Probes · doi:10.1006/mcpr.1993.1034 · Cited by 239
Longitudinal change in basal ganglia volume in patients with Huntington's disease
Aylward, E. H., Li, Q., Stine, O. C., Ranen, N., Sherr, M., Barta, P. E., Bylsma, F. W., Pearlson, G. D., & Ross, C. A. (1997) · Neurology · doi:10.1212/wnl.48.2.394 · Cited by 217
Cited by
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Detection of Huntington's disease decades before diagnosis: the Predict-HD study
Paulsen, J. S., Langbehn, D. R., Stout, J. C., Aylward, E., Ross, C. A., Nance, M., Guttman, M., Johnson, S., MacDonald, M., Beglinger, L. J., et al. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.128728 · Cited by 804
Self-citationMicroglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440
Metadata
- Authors
- Paulsen, J. S.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-06-01
- Volume
- 63
- Issue
- 6
- Pages
- 883
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2110684391
- Cited by
- 291
- References
- 29
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preparing for Preventive Clinical Trials: The Predict-HD Study. https://app.cochat.ai/papers/10.1001/archneur.63.6.883
- The paper
- Paulsen, J. S. (2006). Preparing for Preventive Clinical Trials: The Predict-HD Study. Archives of Neurology. https://doi.org/10.1001/archneur.63.6.883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.